Skip to main content
NCBI home page
Blood logoLink to Blood
letter
. 2016 Oct 20;128(16):2100–2103. doi: 10.1182/blood-2016-08-731943

Normal hematologic parameters and fetal hemoglobin silencing with heterozygous IKZF1 mutations

Nour Abdulhay 1,2,3,*, Claudia Fiorini 1,2,3,*, Attila Kumánovics 4,5, Ashleigh A Sun 6, Jeannette Hansen-Rejali 4,5,7, Karl V Voelkerding 4,5, Sergio D Rosenzweig 6, Harry R Hill 4,5,7, Vijay G Sankaran 1,2,3,✉
PMCID: PMC5073187  PMID: 27581358

To the editor:

The multiple zinc finger-containing transcription factor, IKAROS/IKZF1, has multifaceted roles in hematopoiesis.1 Numerous studies using both human primary hematopoietic cells and mouse models have suggested that IKZF1 plays a key role in erythropoiesis and the fetal-to-adult hemoglobin (Hb) switch.2-7 Even with partial suppression of IKZF1, fetal Hb (HbF) silencing appeared to be impaired in these model systems.4,7 In addition, extensive studies of various mouse models have demonstrated that Ikzf1 is necessary for hematopoietic stem cell (HSC) maintenance, lymphoid-priming in early multipotential hematopoietic progenitors, B- and T-lymphopoiesis, and suppression of specific myeloid lineages. Ikzf1 knockout mice have a 30- to 40-fold reduction in HSCs, an absence of all B- and T-lymphoid precursors, and an increase in the number of myeloid precursors, including those giving rise to megakaryocytes, basophils, and neutrophils.1,8-10 Ongoing work is focused on understanding the mechanisms through which IKZF1 is able to mediate these various activities during hematopoiesis through association with chromatin regulatory complexes.1,11 However, recent findings have also highlighted key differences in aspects of hematopoiesis observed in humans compared with various model systems.12-15 Importantly, a study in primary human hematopoietic cells has shown that suppression of IKZF1 does not alter HbF silencing and has little effect on erythropoiesis,16 in contrast with other earlier studies.4,7 Thus, analysis of human IKZF1 mutations in vivo would enhance our understanding of this gene’s function, similar to the manner in which other human genetic studies have provided key insights into hematopoiesis and Hb gene regulation.15,17-21 For example, haploinsufficiency of the multiple zinc finger-containing transcription factor BCL11A in humans is sufficient to allow high-level persistence of HbF, validating this factor as a key therapeutic target for HbF induction to treat patients with sickle cell disease (SCD) and β-thalassemia.17,18,22-24

Recently, an autosomal dominant form of a common variable immunodeficiency (CVID)-like syndrome with progressive B lymphopenia and an increased risk of hematologic malignancies was associated with heterozygous loss-of-function mutations in IKZF1.25 Despite an extensive analysis of immunologic parameters in these individuals, hematologic phenotypes were not obviously apparent or described. We therefore performed hematologic analyses (including complete blood counts [CBCs], white blood cell [WBC] subset assessments, and Hb subtype quantification) on a total of 16 affected individuals carrying IKZF1 mutations and 11 unaffected family members from 2 separate pedigrees (Table 1; Figure 1). Approval for this study was obtained from the Institutional Review Boards at the National Institutes of Health, the University of Utah, and Boston Children’s Hospital. Informed consent for this study was provided according to the Declaration of Helsinki. Family C has a c.500A>G mutation resulting in the H167R loss-of-function missense mutation, whereas Family F has a 4.7 Mb heterozygous deletion on chromosome 7 involving one IKZF1 allele (Figure 1).25

Table 1.

Hematologic parameters for individuals from Families C and F

Family C Family F Normal range
c.500A→G (p.H167R) 4.7-Mb deletion on chromosome 7
Subject C1 C1A C2 C3 C1B F1 F2 F3 F4 F4A F4B F5 F5A F5B F5C F5D F6 F7 F8 F9 F10 F11 F12 F13 F14 F14B F14D —
Sex F M F F F F F M M M F F M M F F M F F M M M M M M M F —
Age 49 47 18 16 14 64 71 39 37 10 6 35 11 3 12 6 48 14 10 8 23 21 19 16 44 12 11 —
Affected/
Unaffected (A/U)		 A U A A U A A A A U U A U* U* U* U* A A A A A A A A U U U —
WBC, K/μL 9.01 6.34 7.58 9.68 13.08 6.10 3.95 4.70 6.45 7.04 8.36 8.62 8.4 9.84 10.7 7.32 5.40 4.81 5.95 4.74 7.87 8.9 8.68 6.98 10.33 6.32 5.67 3.98-10.04
RBC, M/μL 4.80 5.13 5.08 4.80 4.63 3.40 4.51 4.79 4.65 4.14 3.69 4.31 4.7 3.7 4.71 4.33 5.5 4.98 5.02 4.33 5.19 5.18 4.97 5.13 5.06 4.74 4.35 3.93-5.22
Hb, g/dL 13.9 16.3 13.1 14.6 13.7 10.2 13.9 15.1 14.8 12.2 10.5 13.0 13.6 10.5 13.7 12.5 16.1 14.7 13.9 12.1 16.9 17.4 16.0 16.6 15.2 14.0 13.2 11.0-17.0
HCT, % 41.5 46.9 40.7 42.1 40.3 32.3 43.1 45.8 45.0 37.5 33.2 42.4 42.7 33.2 42.8 39.1 50.6 46.9 43.8 38.8 50.1 52.8 47.9 49.9 49.1 44.6 41.1 34.0-50.0
MCV, fL 86.5 91.4 80.1 87.7 87.0 95.0 95.6 95.6 96.8 90.6 90.0 98.4 90.9 89.7 90.9 90.3 92.0 94.2 87.3 89.6 96.5 101.9 96.4 97.3 97.0 94.1 94.5 79.4-96.0
MCH, pg 29.0 31.8 25.8 30.4 29.6 30.0 30.8 31.5 31.8 29.5 28.5 30.2 28.9 28.4 29.1 28.9 29.3 29.5 27.7 27.9 32.6 33.6 32.2 32.4 30.0 29.5 30.3 25.6-33.0
MCHC, g/dL 33.5 34.8 32.2 34.7 34.0 31.6 32.3 33.0 32.9 32.5 31.6 30.7 31.9 31.6 32.0 32.0 31.8 31.3 31.7 31.2 33.7 33.0 33.4 33.3 31.0 31.4 32.1 32.2-35.5
RDW, % 12.7 12.6 14.1 13.1 12.7 14.1 14.9 13.8 14.1 12.9 13.3 13.4 13.3 14.4 13.2 13.4 14.6 13.5 14.3 13.0 13.5 13.3 14.3 14.0 12.7 13.4 12.3 11.7-14.4
Platelet count, K/μL 361 209 279 231 329 254 185 225 179 285 291 350 333 448 430 371 207 273 281 266 230 354 315 288 344 416 353 173-369
MPV, fL 10.0 11.0 10.2 10.0 8.9 11.4 10.6 11.0 11.8 10.0 10.08 10.4 10.9 10.2 10.0 10.1 9.5 9.8 10.1 10.5 9.6 8.6 9.2 8.8 11.0 11.0 11.2 9.4-12.3
Nucleated RBCs, K/μL 0.00 0.00 0.00 0.00 0.00 0.00 0.0 0.00 0.02 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 0.01 <0.01 <0.01 <0.01 <0.01 0.00-0.01
Neutrophils, K/μL 4.51 3.66 3.84 4.25 10.15 3.43 1.45 3.13 2.49 3.35 3.86 5.08 4.02 4.23 4.69 2.76 3.03 2.44 2.48 1.51 3.97 4.18 3.38 3.70 6.33 3.42 2.46 1.56-6.13
Absolute lymphocytes, K/μL 3.36 1.98 2.81 4.60 1.85 1.86 2.11 1.02 3.26 2.76 3.78 2.67 3.29 4.82 4.81 3.66 1.73 1.75 2.51 2.65 2.87 3.86 4.10 2.21 2.78 2.00 2.52 1.18-3.74
Absolute monocytes, K/μL 0.77 0.49 0.74 0.78 0.88 0.64 0.37 0.35 0.58 0.47 0.52 0.59 0.62 0.65 0.91 0.63 0.52 0.44 0.56 0.46 0.62 0.6 0.81 0.74 0.69 0.52 0.49 0.24-0.86
Absolute eosinophils, K/μL 0.21 0.13 0.09 0.00 0.08 0.12 <0.03 0.14 0.05 0.42 0.15 0.19 0.39 0.07 0.17 0.19 <0.03 0.12 0.35 0.06 0.26 0.17 0.25 0.20 0.41 0.31 0.17 0.04-0.36
Absolute basophils, K/μL 0.09 0.05 0.05 0.05 0.06 0.03 <0.03 0.04 0.05 0.04 0.03 0.06 0.05 0.04 0.07 0.06 0.09 0.04 0.04 0.04 0.12 0.06 0.12 0.12 0.08 0.06 <0.03 0.00-0.10
Reticulocyte, % — — — — — 1.4 1.3 1.0 1.1 0.9 0.9 1.5 1.2 1.7 1.4 1.4 1.8 0.9 0.8 0.8 2.5 3.3 2.7 2.2 1.5 1.4 1.3 0.5-2.0
Absolute reticulocytes, K/μL — — — — — 46.9 60.0 46.5 49.3 37.7 33.6 64.7 56.6 62.9 64.1 60.6 96.8 44.8 41.2 34.6 126.0 171.5 134.2 113.9 77.4 68.3 56.1 —
HbF, % 1.5 1.1 1.1 0.5 0.8 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 1.5 0.8 0.3 0.2 0.2 0.4 0.2 0.2 0.7 0.2 0.2 0.3 0.3 0.9 <2.0
HbA2, % 2.2 2.5 2.1 2.1 2.7 2.8 2.9 2.9 3.1 2.8 3.2 2.7 3.2 3.1 3.0 3.0 3.0 2.8 2.7 3.2 3.0 3.1 2.9 2.9 3.0 2.9 3.1 <3.5
Open in a new tab

HCT, hematocrit; MCH, mean corpuscular Hb; MCHC, MHC concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; RBC, red blood cell; RDW, RBC distribution width.

Figure 1.

Figure 1

Open in a new tab

Pedigrees of families with IKZF1 mutations. Families C and F are shown. Female (circle) and male (square) individuals are shown in the 2 pedigrees and the shaded shapes indicate individuals who are affected by a CVID-like syndrome due to heterozygous IKZF1 mutations. Individuals with hematologic phenotypes available are labeled in the pedigrees and correspond to the labeling shown in Table 1. *Indicates individuals who are clinically unaffected, but for whom molecular testing results are not yet available.

CBC results revealed that nearly all blood cell parameters were within the normal range in both affected individuals and unaffected family members (Table 1). No defects in either RBC, platelet, or WBC subtype numbers or parameters were observed with the exception of very mild macrocytosis and reticulocytosis observed in siblings F10-F13. Given the absence of similar findings in other family members carrying the identical IKZF1 deletion, we suspect that these altered parameters may be due to a different genetic or environmental etiology (Table 1). Although we cannot entirely rule out whether subtle defects in precursors may be present in the bone marrow of all of the affected individuals in Families C and F, blood counts are remarkably sensitive indicators of variation in hematopoiesis. We do note a trend toward higher basophil counts in several affected individuals (eg, C1, F6, F10, F12, and F13), consistent with the known role of IKZF1 in restricting basophil production.9 Other myeloid lineages appeared to be within the normal ranges consistently in all individuals. Importantly, we observed no significant alteration in Hb subtype levels, and specifically in HbF levels, in any of the affected individuals (Table 1). Although greater suppression of IKZF1 may be necessary to observe altered hematopoiesis or globin gene regulation, our results suggest that heterozygous loss-of-function, resulting in a reduced level of IKZF1 sufficient to alter B-lymphocyte production and function, is insufficient to alter other hematologic parameters or HbF silencing. This phenotype contrasts with those observed for mutations in other related factors such as BCL11A, to which IKZF1 has been suggested to bind in erythroid cells.7 Haploinsufficiency for BCL11A can result in substantial persistence of HbF of >10%.17,18,22

It is noteworthy that we were able to evaluate 2 families with different types of heterozygous IKZF1 mutations: a missense change in Family C and a complete gene deletion in Family F. Because IKZF1 predominantly acts as a homodimeric transcription factor, affected members in Family F are expected to produce only ∼50% of IKZF1 wild-type (WT)/WT homodimers, whereas affected individuals in Family C should make ∼25% of such dimers (plus ∼25% of mutant/mutant and ∼50% of WT/mutant dimers).25 Thus, the normal hematologic parameters and similar levels of Hb subtypes observed in the 2 families suggest that although ∼50% of WT/WT IKZF1 dimers are not sufficient to support physiologic B-cell development and function, ∼25% of them are enough to ensure otherwise normal hematopoiesis.

More generally, our analysis emphasizes the utility of in-depth human genetic studies and phenotyping to validate the role of key regulators in human hematopoiesis and Hb gene regulation. Indeed, given the differences in hematopoiesis between humans and the various models systems employed, it is likely that many other examples of variation in phenotypes and the necessity of particular genes may be observed.13,14 For example, although heterozygous Bcl11a mutations in mice cause immunologic defects, this was not observed in humans with BCL11A haploinsufficiency.17,22 With considerable efforts being dedicated to induce HbF for therapeutic purposes to treat SCD and β-thalassemia,24 there is a need to not only rely on animal and cell culture models, which have tremendous value and provide considerable insight, but to attempt to validate findings in vivo in humans whenever possible. Emerging biobanks and precision medicine efforts are likely to provide incredibly valuable resources to help identify relevant and effective therapeutic opportunities. We emphasize the importance of careful and thorough observations of human subjects to validate and gain insight into hematopoiesis, based on findings from valuable model systems.

Authorship

Acknowledgments: The authors are grateful to the families described here for their willingness to participate in this study, and the members of the Sankaran laboratory for valuable comments and suggestions.

This work was supported by grants from the National Institutes of Health (National Heart, Lung, and Blood Institute U01 HL117720 and R33 HL120791; and National Institute of Diabetes and Digestive and Kidney Diseases R01 DK103794) (V.G.S.), as well as the National Institute of Allergy and Infectious Diseases (R03 AI113631) (A.K., K.V.V., and H.R.H.).

Contribution: N.A., C.F., H.R.H., S.D.R., and V.G.S. designed the research and wrote the manuscript with input from A.K., A.A.S., J.H.-R., and K.V.V.; and all authors gathered and analyzed clinical data.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Vijay G. Sankaran, Division of Hematology/Oncology, Boston Children’s Hospital, 3 Blackfan Cir, CLS 03001, Boston, MA 02115; e-mail: sankaran@broadinstitute.org.

References

  • 1.Yoshida T, Ng SY, Georgopoulos K. Awakening lineage potential by Ikaros-mediated transcriptional priming. Curr Opin Immunol. 2010;22(2):154–160. doi: 10.1016/j.coi.2010.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lopez RA, Schoetz S, DeAngelis K, O’Neill D, Bank A. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci USA. 2002;99(2):602–607. doi: 10.1073/pnas.022412699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Keys JR, Tallack MR, Zhan Y, et al. A mechanism for Ikaros regulation of human globin gene switching. Br J Haematol. 2008;141(3):398–406. doi: 10.1111/j.1365-2141.2008.07065.x. [DOI] [PubMed] [Google Scholar]
  • 4.Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. The role of Ikaros in human erythroid differentiation. Blood. 2008;111(3):1138–1146. doi: 10.1182/blood-2007-07-098202. [DOI] [PubMed] [Google Scholar]
  • 5.Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013;3(1):a011643. doi: 10.1101/cshperspect.a011643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bottardi S, Ross J, Bourgoin V, et al. Ikaros and GATA-1 combinatorial effect is required for silencing of human gamma-globin genes. Mol Cell Biol. 2009;29(6):1526–1537. doi: 10.1128/MCB.01523-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Xu J, Bauer DE, Kerenyi MA, et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci USA. 2013;110(16):6518–6523. doi: 10.1073/pnas.1303976110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Malinge S, Thiollier C, Chlon TM, et al. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood. 2013;121(13):2440–2451. doi: 10.1182/blood-2012-08-450627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Rao KN, Smuda C, Gregory GD, Min B, Brown MA. Ikaros limits basophil development by suppressing C/EBP-α expression. Blood. 2013;122(15):2572–2581. doi: 10.1182/blood-2013-04-494625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dumortier A, Kirstetter P, Kastner P, Chan S. Ikaros regulates neutrophil differentiation. Blood. 2003;101(6):2219–2226. doi: 10.1182/blood-2002-05-1336. [DOI] [PubMed] [Google Scholar]
  • 11.Bottardi S, Mavoungou L, Pak H, et al. The IKAROS interaction with a complex including chromatin remodeling and transcription elongation activities is required for hematopoiesis. PLoS Genet. 2014;10(12):e1004827. doi: 10.1371/journal.pgen.1004827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093–1097. doi: 10.1038/nature08243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ulirsch JC, Lacy JN, An X, Mohandas N, Mikkelsen TS, Sankaran VG. Altered chromatin occupancy of master regulators underlies evolutionary divergence in the transcriptional landscape of erythroid differentiation. PLoS Genet. 2014;10(12):e1004890. doi: 10.1371/journal.pgen.1004890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Nandakumar SK, Ulirsch JC, Sankaran VG. Advances in understanding erythropoiesis: evolving perspectives. Br J Haematol. 2016;173(2):206–218. doi: 10.1111/bjh.13938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122(7):2439–2443. doi: 10.1172/JCI63597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dulmovits BM, Appiah-Kubi AO, Papoin J, et al. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood. 2016;127(11):1481–1492. doi: 10.1182/blood-2015-09-667923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Basak A, Hancarova M, Ulirsch JC, et al. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. J Clin Invest. 2015;125(6):2363–2368. doi: 10.1172/JCI81163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Funnell AP, Prontera P, Ottaviani V, et al. 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood. 2015;126(1):89–93. doi: 10.1182/blood-2015-04-638528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sankaran VG, Menne TF, Šćepanović D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA. 2011;108(4):1519–1524. doi: 10.1073/pnas.1018384108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sankaran VG, Joshi M, Agrawal A, et al. Rare complete loss of function provides insight into a pleiotropic genome-wide association study locus. Blood. 2013;122(23):3845–3847. doi: 10.1182/blood-2013-09-528315. [DOI] [PubMed] [Google Scholar]
  • 21.Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med. 2011;365(9):807–814. doi: 10.1056/NEJMoa1103070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dias C, Estruch SB, Graham SA, et al. DDD Study. BCL11A haploinsufficiency causes an intellectual disability syndrome and dysregulates transcription. Am J Hum Genet. 2016;99(2):253–274. doi: 10.1016/j.ajhg.2016.05.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839–1842. doi: 10.1126/science.1165409. [DOI] [PubMed] [Google Scholar]
  • 24.Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221–230. doi: 10.1038/nm.3814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N Engl J Med. 2016;374(11):1032–1043. doi: 10.1056/NEJMoa1512234. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Blood are provided here courtesy of The American Society of Hematology

RESOURCES